|
|
|
|
TopAbstracts in Viral Infections 01/05/2009
TopAbstracts in Viral Infections are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 14 days.Over 2000 peer...
|
|
|
Pica and Refractory Iron Deficiency Anaemia: A Case Report
_ Pica and Refractory Iron Deficiency Anaemia: A Case Report.
|
|
|
A Phase II Pilot Study to Evaluate Use of Intravenous Lidocaine for Opioid-Refractory Pain in Cancer Patients
Sharma S et al.- The data demonstrate that a single IV infusion of lidocaine provided a significantly greater magnitude and duration of pain relief than placebo infusion in opioid-refractory patients with cancer pain. Side effects were...
|
|
|
PAION And ERGOMED Complete Enrolment Of Phase IIa Study With CNS 5161 In Opioid-Refractory Cancer Pain
The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8; London AIM: PAI) and ERGOMED Clinical Research Limited today announce the completion of an open-label, single-centre Phase IIa study...
|
|
|
Supernus Pharmaceuticals Initiates Phase III Clinical Trial For Epliga In Refractory Partial Onset Epileptic S
announced the initiation of the pivotal Phase III clinical trial for its lead product Epliga.The trial is a randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of Epliga for the adjunctive treatment...
|
|
|
Acute Cytomegalovirus Infection Is a Risk Factor in Refractory and Complicated Inflammatory Bowel Disease
Maher MM et al.- High clinical index of suspicion for the association of CMV infection with IBD should be directed towards female IBD patients presenting with fever, lymphadenopathy, splenomegaly, leucopenia, and mild hepatitis. Acute...
|
|
|
PAION And ErgoMed Complete Enrolment of Phase IIa Study with CNS 5161 in Opioid-Refractory Cancer Pain
AACHEN & FRANKFURT, Germany--(BUSINESS WIRE)--The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8; London AIM: PAI) and ERGOMED Clinical Research Limited today announce the completion...
|
|
|
PAION and ERGOMED Complete Enrolment of Phase IIa Study with CNS 5161 in Opioid-Refractory Cancer Pain
The biopharmaceutical company AG (News/Aktienkurs) (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8; London AIM: PAI) and ERGOMED Clinical Research Limited today announce the completion of an open-label, single-centre Phase...
|
|
|
PAION and ERGOMED Complete Enrolment of Phase IIa Study with CNS 5161 in Opioid-Refractory Cancer Pain
AACHEN & FRANKFURT, Germany--(BUSINESS WIRE)--The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8; London AIM: PAI) and ERGOMED Clinical Research Limited today announce the completion...
|
|
|
Dexmedetomidine and Refractory Cardiogenic Shock
_ Dexmedetomidine and Refractory Cardiogenic Shock.
|
|
|
Supernus Pharmaceuticals Initiates Phase III Clinical Trial for Epliga in Refractory Partial Onset Epileptic
- Supernus Pharmaceuticals, Inc.today announced the initiation of the pivotal Phase III clinical trial for its lead product Epliga. The trial is a randomized, double-blind, placebo-controlled study to investigate the efficacy and safety...
|
|
|
::: Supernus Pharmaceuticals Initiates Phase III Clinical Trial for Epliga in Refractory Partial Onset Epilep
Once-Per-Day Therapy is Designed to Improve Patient Compliance and Reduce Adverse Events as Compared with Reference Product Trileptal ROCKVILLE, Md.--(BUSINESS WIRE)--Supernus Pharmaceuticals, Inc.today announced the initiation of the...
|
|
|
Supernus Pharmaceuticals Initiates Phase III Clinical Trial for Epliga in Refractory Partial Onset Epileptic S
Epliga is a novel controlled release once-per-day dosage form of oxcarbazepine that is designed to improve compliance and reduce adverse events.Earlier this year, Supernus completed a proof-of-concept study where Epliga showed significant...
|
|
|
Supernus Pharmaceuticals Initiates Phase III Clinical Trial for Epliga? in Refractory Partial Onset Epileptic
Supernus Pharmaceuticals, Inc.today announced the initiation of the pivotal Phase III clinical trial for its lead product Epliga'. The trial is a randomized, double-blind, placebo-controlled study to investigate the efficacy and safety...
|
|
|
Supernus Pharmaceuticals Initiates Phase III Clinical Trial for Epliga in Refractory Partial Onset Epileptic S
Once-Per-Day Therapy is Designed to Improve Patient Compliance and Reduce Adverse Events as Compared with Reference Product Trileptal ROCKVILLE, Md.--(BUSINESS WIRE)--Dec 17, 2008 - Supernus Pharmaceuticals, Inc.today announced the...
|
|
|
Supernus Pharmaceuticals Initiates Phase III Clinical Trial for Epliga„ in Refractory Partial Onset Ep
today announced the initiation of the pivotal Phase III clinical trial for its lead product Epliga„.The trial is a randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of Epliga for the...
|
|
|
Supernus Pharmaceuticals Initiates Phase III Clinical Trial for Epliga„ in Refractory Partial Onset Ep
ROCKVILLE, Md.--(BUSINESS WIRE)-- today announced the initiation of the pivotal Phase III clinical trial for its lead product Epliga".The trial is a randomized, double-blind, placebo-controlled study to investigate the efficacy and safety...
|
|
|
Supernus Pharmaceuticals Initiates Phase III Clinical Trial for Epliga™ in Refractory Partial Onset Epil
ROCKVILLE, Md.- (Business Wire) today announced the initiation of the pivotal Phase III clinical trial for its lead product Epliga. The trial is a randomized, double-blind, placebo-controlled study to investigate the efficacy and safety...
|
|
|
Treatment of Refractory Oral Erosive Lichen Planus with Topical Rapamycin: 7 Cases
Journal of the European Academy of Dermatology and Venereology, 10/24/08 Journal Treatment of Refractory Oral Erosive Lichen Planus with Topical Rapamycin: 7 Cases.
|
|
|
Weighing the Options and Managing the Patient With RA Refractory to Treatment
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View...
|
|
|
Weighing the Options and Managing the Patient With RA Refractory to Treatment
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View...
|
|
|
Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma
Proteolix, Inc.today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma.
|
|
|
Data from Eight Clinical Trials Facilitated by the Multiple Myeloma Research Consortium (MMRC) Presented at th
MMRC Multiple Myeloma Genomics Initiative Data Presented at Oral Session NORWALK, Conn.--(BUSINESS WIRE)--Dec 10, 2008 - The Multiple Myeloma Research Consortium (MMRC) today announced that data from eight clinical trials in its portfolio as...
|
|
|
Data From Eight Clinical Trials Facilitated By The Multiple Myeloma Research Consortium (MMRC) Presented At Th
The today announced that data from eight clinical trials in its portfolio as well as findings from the MMRC Multiple Myeloma Genomics Initiative were presented at the American Society of Hematology's (ASH) 50th Annual Meeting and Exposition...
|
|
|
Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials Of Carfilzomib In Multiple Myeloma
Proteolix, Inc.announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma. Carfilzomib...
|
